- Home
- EIM vs KMDA Comparison
EIM vs KMDA Comparison
Compare EIM & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIM | KMDA |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 460.3M |
| IPO Year | 2002 | 2013 |
Fundamental Metrics
Financial Performance| Metric | EIM | KMDA |
|---|---|---|
| Price | $9.77 | $7.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 130.6K | 33.0K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.94 |
| Revenue Next Year | N/A | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.42 | $6.50 |
| 52 Week High | $10.54 | $9.35 |
Technical Indicators
Market Signals| Indicator | EIM | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 42.50 | 42.20 |
| Support Level | $9.67 | $7.00 |
| Resistance Level | $10.04 | $7.16 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 23.53 | 25.61 |
Price Performance
Historical ComparisonAbout EIM Eaton Vance Municipal Bond
Eaton Vance Municipal Bond Fund is a non-diversified closed-end management investment company. It consists of Municipal bond fund, California municipal bond fund, and New York municipal bond fund. The company's investment objective is to provide current income exempt from regular federal income tax, alternative minimum tax, and taxes in specified states. Its investment plan is to invest in higher quality bonds.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.